Vitamin D receptor genotypes influence quadriceps strength in chronic obstructive pulmonary disease

Nicholas S Hopkinson, Ka Wah Li, Anthony Kehoe, Steve E Humphries, Michael Roughton, John Moxham, Hugh Montgomery, and Michael I Polkey

ABSTRACT

Background: Quadriceps weakness is an important complication of chronic obstructive pulmonary disease (COPD) and is associated with impaired exercise capacity and greater mortality. Its etiology is multifactorial, and evidence is growing that it is partly determined by genetic susceptibility.

Objective: Using an established cohort, we tested whether quadriceps weakness in patients with COPD is influenced by common variations in the gene for the vitamin D receptor.

Design: Vitamin D receptor FokI and BsmI genotypes and the (I/D) angiotensin-converting enzyme (ACE) and bradykinin receptor (+9/−9) genotypes were identified in 107 patients with stable COPD [± SD forced expiratory volume in 1 s (FEV1); 34.5 ± 16.5] and 104 healthy, age-matched control subjects. Quadriceps maximum voluntary contraction force and fat-free mass assessed by bioelectrical impedance analysis were measured.

Results: After adjustment for covariables, both patients and control subjects who were homozygous for the C allele of the FokI polymorphism had less quadriceps strength than did those with ≥1 T allele [41.0 ± 11.8 compared with 46.0 ± 13.2 kg (P = 0.01) and 32.5 ± 11.2 compared with 36.2 ± 13.1 kg (P = 0.005), respectively]. The b allele of the BsmI polymorphism was associated with greater quadriceps strength in patients—37.0 ± 13.3, 33.8 ± 11.6, and 33.8 ± 11.6 kg for bb, bb, and BB, respectively (P = 0.0005)—but had no effect in healthy control subjects. The effect of BsmI on quadriceps strength was least apparent in patients with the ACE II genotype (P = 0.003).

Conclusions: The FokI common variants in the VDR gene are associated with skeletal muscle strength in both patients and control subjects, whereas the BsmI polymorphism is associated with strength only in patients. Am J Clin Nutr 2008;87:385–90.

KEY WORDS Muscle, quadriceps, angiotensin-converting enzyme, bradykinin

INTRODUCTION

Quadriceps weakness is an important systemic consequence of chronic obstructive pulmonary disease (COPD) and is associated with a decreased exercise capacity (1–4). Moreover, reduced quadriceps bulk (5) and strength (6) are associated with greater mortality. Several etiologic factors have been proposed, including disuse atrophy, systemic inflammation, hormonal dysfunction, and systemic corticosteroid treatment (7).

Twin studies have shown that there is a significant genetic component to muscle strength (8, 9). A study of lower-limb strength in elderly male twins found that genetic factors appeared to be more significant in the poorest quartile of performance, and environmental factors appeared more significant as determinants of good performance (9). It seems reasonable to assume that susceptibility to the systemic effects of COPD should to some extent be genetically determined. In support of this, we have shown associations between quadriceps strength and both the I/D polymorphism of the angiotensin-converting enzyme (ACE) and the +9/−9 polymorphism of the bradykinin receptor (BK,R) in patients with COPD (10, 11). Vitamin D has a well-described role in calcium metabolism, increasing the absorption of calcium and phosphate from the intestine and increasing renal calcium reabsorption. It has been suggested that vitamin D also may have an important role in influencing skeletal muscle function (12), and vitamin D receptors have been identified in this tissue (13).

Several VDR polymorphisms exist that are associated with a range of biological effects on variables, including bone mineral density, immune response, and susceptibility to a range of diseases such as osteoarthritis, diabetes, cancer, cardiovascular disease, and tuberculosis (14). FokI, a polymorphism involving a T→C transition in exon 2 of the VDR gene, changes the site at which translation is initiated. Persons with the C allele (sometimes designated “F”) have a shorter 424-amino acid VDR than do persons with the T (“T”) allele, which is 427 amino acids long. The shorter VDR appears to have enhanced transactivation capacity as a transcription factor (15–17). The C allele of FokI has been associated with reduced fat-free mass (FFM) and quadriceps strength in otherwise healthy elderly men (18).

BsmI is a restriction fragment length polymorphism at the 3′ end of the VDR gene that has also been found to be associated with...
with skeletal muscle function. The \( b \) (rather than \( B \)) allele was associated with lower FFM and hamstring (but not quadriceps) strength in healthy young women aged 20–39 y (19), whereas, in nonobese elderly women, both handgrip and quadriceps strength were higher in those with the \( bb \) genotype (20).

Given the association of impaired skeletal muscle function with COPD, and the association of \( VDR \) genotype with muscle function in other population samples, we sought a similar association of \( VDR \) \( FokI \) and \( BsmI \) genotypes with muscle strength in a group of COPD patients and age-matched healthy subjects in whom the association of \( ACE \) and \( BK_{R}R \) genotypes with strength was shown previously (10, 11).

SUBJECTS AND METHODS

Subjects

Data from this group of subjects were published previously (10, 11). Briefly, patients with COPD, defined in accordance with the criteria of the Global Initiative for Chronic Obstructive Pulmonary Disease (Internet: www.goldcopd.com), were recruited from hospital clinics. Subjects with significant comorbidity including heart failure, diabetes, malignancy, and neuromuscular disease were excluded. Healthy age-matched control subjects were recruited by advertisement in local newspapers.

All participants provided written informed consent. The study was approved by the Ethics Committee of The Royal Brompton and Harefield NHS Trust.

Methods

FFM was measured by using a bioelectrical impedance device (Bodystat 1500; Bodystat, Douglas, United Kingdom). For patients, a disease-specific regression equation was used (21), and, for healthy subjects, the device’s internal algorithm was used. Pulmonary function (gas transfer, plethysmographic lung volumes and spirometry in patients, and spirometry only in controls) was assessed by using a CompactLab system (Jaeger, Würzburg, Germany). Quadriceps strength, calculated as quadriceps maximum voluntary contraction force (QMVC), was measured while subjects were seated in a custom-designed chair with their legs bent at the knees to 90 degrees. An inextensible strap connected the subject’s ankle to a strain gauge. The signal was amplified and passed to a computer running LABVIEW software (version 4.1; National Instruments, Austin, TX). The force generated was visible online, and subjects received vigorous encouragement. The best of \( \geq3 \) efforts was taken.

In control subjects, handgrip strength also was measured by using a Jamar handgrip dynamometer (Sammons Preston Rolyan, Bolingbrook, IL). Subjects performed 6 maximum contractions \( \geq30 \) s apart, alternating hands. The mean of the peak value for each hand was recorded.

Genotyping

\( VDR \) \( FokI \) genotypes (rs 10735810) were identified by using the forward primer \( 5^{\prime} \) GGCCCTGTTGTGCTTCTAAC 3’ and reverse primer \( 5^{\prime} \) TGCTTCTTCTCCCTCCCTTT 3’. \( VDR \) \( BsmI \) genotypes (rs 1544410) were identified by using the forward primer \( 5^{\prime} \) CCTCAGCCCTT/AAGCTTG 3’ and reverse primer \( 5^{\prime} \) CCATCTCTAGGCTTCAAG 3’. Polymerase chain reaction (PCR) was performed by using a thermal cycler (PTC-225; MJ Research, Watertown, MA), and digestion products were run on 7.5% polyacrylamide gels. All genotypes were scored by 2 independent technicians (blinded as to subject status), and any discrepancies were resolved by repeat genotyping. \( ACE \) \( V \) and \( BK_{R}R + 9|-9 \) genotypes were identified as reported previously (10, 11).

Statistical analysis

Analyses were performed with STATVIEW software (version 5.0; Abacus Concepts Inc, Berkeley, CA); they focused on the effect of the \( VDR \) genotype on QMVC. A hierarchy of models was analyzed in all subjects including potential confounders [ie, age, sex, FFM, and forced expiratory volume in 1 s (FEV\(_1\))] and a term to test for differences between patient and control subjects and also including the various genotypes to test for significant interactions. Interactions between the \( VDR \) genotype and \( ACE \) and \( BK_{R}R \) genotype were also sought. An effect of the \( ACE \) genotype was considered across all 3 genotypes. For the \( BK_{R}R \) genotype, a binary approach comparing +9 homozygotes to the other 2 genotypes was used (10, 11). For \( FokI \), \( C \) homozygotes were compared with the other 2 genotypes, whereas \( BsmI \) was analyzed across all 3 genotypes, as is consistent with previous studies (18, 20). In the COPD population, gas transfer [carbon monoxide transfer factor (TLCO)] was used instead of FEV\(_1\) as an index of disease severity, because it is known that muscle wasting in COPD patients is correlated with the degree of emphysema more strongly than is the severity of airflow limitation (22, 23). Continuous variables are expressed as means \( \pm \) SDs. \( P \) \( <0.05 \) was taken as statistically significant.

RESULTS

Data were available for 104 healthy control subjects and 107 COPD patients. \( BsmI \) genotyping failed in 1 patient. COPD patients had a significantly (\( P \) \( <0.05 \)) lower FFM index and QMVC than did controls (Table 1). The allele frequencies of the \( VDR \), \( ACE \) and \( BK_{R}R \) polymorphisms did not differ significantly between patients and control subjects, and the distribution of genotypes was as expected for Hardy-Weinberg proportions. There was no evidence of linkage disequilibrium between \( FokI \) and \( BsmI \) polymorphisms (\( D^{\prime} \), \( -0.03; R^{2} <0.005; P \) \( =0.6 \)).

\( FokI \) genotype

In the entire sample, \( FokI \) \( C \)-homozygous subjects had significantly weaker quadriceps than did subjects with 1 or 2 \( T \) alleles: \( 36.5 \pm 12.2 \text{ kg} \) compared with \( 41.2 \pm 14.0 \text{ kg} \) (\( P \) \( =0.01 \), Scheffe test) (Figure 1). This difference became more significant (\( P \) \( =0.002 \)) in a model that included age, sex, FFM, FEV\(_1\), and \( ACE \) genotypes. There was no evidence that being a patient or a control subject affected the relation between \( FokI \) genotype and QMVC. In the control group, there was a trend for \( C \) homozygotes to have a lower QMVC than did those with \( \geq1 T \) allele: \( 41.0 \pm 11.8 \text{ kg} \) compared with \( 46.0 \pm 13.2 \text{ kg} \) (\( P \) \( =0.052 \), Scheffe test). This difference became significant (\( P \) \( =0.007 \)) in a model including age, FFM, FEV\(_1\), sex, and \( ACE \) genotype.

In the COPD group, \( C \) homozygotes had significantly lower QMVC than did those with \( \geq1 T \) allele: \( 32.5 \pm 11.2 \text{ kg} \) compared with \( 36.2 \pm 13.1 \text{ kg} \) (\( P \) \( =0.02 \)). Univariate analysis in the COPD patient group showed a relation between QMVC and FFM (\( R \) \( =0.62; P <0.001 \)), TLco (% of predicted) (\( R \) \( =0.23; P \) \( =0.02 \)), and age (\( R \) \( =0.18; P \) \( =0.06 \)) but not with FEV\(_1\) (% of predicted).
or arterial blood gas variables. If TLCO (% of predicted) was used as a measure of disease severity instead of FEV₁ in the model above, the effect of C homozygosity on QMVC became even more significant ($P = 0.005$). No evidence of an interaction between C homozygosity on QMVC and other polymorphisms was found either in an analysis of the whole population or in separate analyses of patients and control subjects.

**BsmI genotype**

In the whole population studied, there was a trend for the $b$ allele of the BsmI polymorphism to be associated with greater QMVC ($P = 0.09$ for linear trend) (Figure 2). In the entire population, the effect of patient group $\times$ genotype interaction for QMVC was not significant ($P = 0.38$). In control subjects alone, there was no significant relation with QMVC. A highly significant association ($P = 0.0005$) existed between BsmI genotype and QMVC in COPD patients in a model including cofactors and the other genotypes studied (Table 2 and Table 3). This model including FFM, age, VDR allele C homozygosity, and ACE genotype explained 45% of the variation in QMVC. QMVC values were 37.0 ± 13.3, 33.8 ± 11.6, and 32.6 ± 12.7 kg for patients with the $bb$, $bB$, and $BB$ BsmI genotypes, respectively. The ACE genotype $\times$ effect of BsmI interaction for QMVC was significant ($P = 0.003$); BsmI had the least effect in patients with the ACE II genotype. $B_kR$ genotype did not interact significantly with either VDR variant studied.

**VITAMIN D RECEPTOR POLYMORPHISMS IN COPD**

### Table 1

<table>
<thead>
<tr>
<th></th>
<th>Control group $(n = 104)$</th>
<th>COPD patients $(n = 107)$</th>
<th>$P$</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (y)</td>
<td>61.8 ± 8.5</td>
<td>63.5 ± 9.5</td>
<td>0.16</td>
</tr>
<tr>
<td>Male (%)</td>
<td>46</td>
<td>70</td>
<td>0.004</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>24.7 ± 3.9</td>
<td>24.0 ± 4.8</td>
<td>0.23</td>
</tr>
<tr>
<td>FFMI (kg/m²)</td>
<td>17.3 ± 2.8</td>
<td>16.4 ± 2.2</td>
<td>0.01</td>
</tr>
<tr>
<td>FEV₁ (% of predicted)</td>
<td>103.2 ± 14.7</td>
<td>34.5 ± 16.5</td>
<td>$&lt; 0.0001$</td>
</tr>
<tr>
<td>QMVC (kg)</td>
<td>44.0 ± 12.8</td>
<td>34.6 ± 16.5</td>
<td>$&lt; 0.0001$</td>
</tr>
<tr>
<td><strong>FokI</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>$CC$</td>
<td>41</td>
<td>47</td>
<td></td>
</tr>
<tr>
<td>$CT$</td>
<td>42</td>
<td>46</td>
<td></td>
</tr>
<tr>
<td>$TT$</td>
<td>22</td>
<td>14</td>
<td></td>
</tr>
<tr>
<td>Frequency of $T$ alleles</td>
<td>0.41 (0.31, 0.50)</td>
<td>0.35 (0.26, 0.44)</td>
<td></td>
</tr>
<tr>
<td><strong>BsmI</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>$bb$</td>
<td>43</td>
<td>36</td>
<td>0.07</td>
</tr>
<tr>
<td>$bB$</td>
<td>47</td>
<td>45</td>
<td></td>
</tr>
<tr>
<td>$BB$</td>
<td>14</td>
<td>25</td>
<td></td>
</tr>
<tr>
<td>Frequency of $B$ alleles</td>
<td>0.36 (0.27, 0.45)</td>
<td>0.45 (0.35, 0.54)</td>
<td></td>
</tr>
</tbody>
</table>

1 COPD, chronic obstructive pulmonary disease; FFMI, fat-free mass index; FEV₁, forced expiratory volume in 1 s; QMVC, quadriceps maximal voluntary contraction force (quadriceps strength).

2 $\bar{x} \pm SD$ (all such values).

3 $\bar{x} \pm SD$ (all such values).

4 $\bar{x}$; 95% CI in parentheses (all such values).

### Table 2

<table>
<thead>
<tr>
<th></th>
<th>$bb$</th>
<th>$bB$</th>
<th>$BB$</th>
<th>$P$</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patients $(n)$</td>
<td>36</td>
<td>45</td>
<td>25</td>
<td></td>
</tr>
<tr>
<td>Age (y)</td>
<td>64.8 ± 8.7</td>
<td>63.7 ± 11.2</td>
<td>61.1 ± 6.9</td>
<td>0.32</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>23.3 ± 5.0</td>
<td>24.2 ± 5.1</td>
<td>24.1 ± 3.50</td>
<td>0.62</td>
</tr>
<tr>
<td>FFMI (kg/m²)</td>
<td>15.8 ± 2.4</td>
<td>16.8 ± 2.2</td>
<td>16.2 ± 1.6</td>
<td>0.11</td>
</tr>
<tr>
<td>FEV₁ (% of predicted)</td>
<td>34.6 ± 16.5</td>
<td>35.4 ± 19.5</td>
<td>26.9 ± 11.3</td>
<td>0.03</td>
</tr>
<tr>
<td>TLCO (% of predicted)</td>
<td>36.9 ± 19.7</td>
<td>39.9 ± 19.0</td>
<td>32.6 ± 14.5</td>
<td>0.29</td>
</tr>
</tbody>
</table>

3 $\bar{x} \pm SD$ (all such values).

4 $\bar{x}$; 95% CI in parentheses (all such values).

5 $P = 0.02$, unpaired $t$ test.

6 $P = 0.001$, unpaired $t$ test.

7 $P = 0.0005$, ANOVA.

### Table 3

<table>
<thead>
<tr>
<th></th>
<th>$bb$</th>
<th>$bB$</th>
<th>$BB$</th>
<th>$P$</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control subjects $(n)$</td>
<td>43</td>
<td>47</td>
<td>14</td>
<td></td>
</tr>
<tr>
<td>Age (y)</td>
<td>61.5 ± 9.8</td>
<td>62.2 ± 8.0</td>
<td>61.0 ± 7.2</td>
<td>0.86</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>23.8 ± 3.41</td>
<td>25.2 ± 4.6</td>
<td>25.5 ± 2.9</td>
<td>0.19</td>
</tr>
<tr>
<td>FFM (kg/m²)</td>
<td>17.1 ± 2.8</td>
<td>17.3 ± 2.9</td>
<td>17.5 ± 2.8</td>
<td>0.90</td>
</tr>
<tr>
<td>FEV₁ (% of predicted)</td>
<td>102.1 ± 16.1</td>
<td>103.0 ± 13.9</td>
<td>107.3 ± 12.7</td>
<td>0.52</td>
</tr>
</tbody>
</table>

5 $P = 0.05$, ANOVA.
The associations between the polymorphisms studied and quadriceps strength did not differ by sex. Corticosteroid exposure, expressed as the average daily dose of prednisone received in the preceding year [mostly administered as short burst courses for acute exacerbations; 13 patients were taking long-term low-dose (ie, <10 mg prednisone/d) steroids], was not associated with quadriceps strength by univariate analysis and did not influence the gene × strength interaction in multivariate analysis.

Handgrip strength was measured only in the control subjects. It was significantly lower in FokI C homozygotes than in those with ≥1 T allele—33.2 ± 8.1 kg compared with 36.9 ± 9.2 kg (P < 0.001)—in a model including FFM, sex, and FEV1. Handgrip strength was not associated with BsmI genotype.

DISCUSSION

The main findings of this study were that the C allele of the FokI polymorphism of the VDR was associated with skeletal muscle strength in both patients and healthy control subjects, whereas the BsmI polymorphism was associated with strength only in patients. There was an interaction between the BsmI and the ACE(II) polymorphisms.

The finding that the C allele of the FokI polymorphism was associated with reduced quadriceps strength in both patients and control subjects is consistent with previous findings in healthy elderly men (18), although, in that study, the association with strength was not significant if adjustment was made for FFM. In contrast, our data show a stronger correlation if QMVC is corrected for FFM. The C allele has been associated with greater VDR activity, which, given the positive association of vitamin D stores and strength, is the opposite of what might be expected. It should be borne in mind, however, that this association may be influenced by other cotranscription factors, so that the effect of genotype-dependent differences may be cell-type-specific or organ-specific. The effect of this variant on strength did not differ between patients and control subjects.

The DNA change creating the BsmI is in strong linkage disequilibrium with any of the other known VDR polymorphisms, which agrees with the findings in the present study (14). The DNA change creating the BsmI is in strong linkage disequilibrium with the polyA variable number of tandem repeats (VNTR) in the 3’ untranslated region (UTR) of the regulatory region of the VDR gene, so that the b allele is associated with a long polyA stretch and the B allele is associated with a short one (19, 39). The 3’ UTR is known to play an important role in regulating gene expression—eg, polymorphisms in this area of the glucocorticoid receptor alpha have been shown to influence mRNA stability (40). There is some evidence that the long polyA stretch may be associated with higher VDR activity in combination with the C allele of FokI. This greater activity could result from increased translational activity, greater mRNA stability, or both (16). These mechanisms remain to be elucidated, however, and studies measuring a range of vitamin D–dependent outcomes have provided conflicting data, as reviewed by Utterlinden et al (14).

The BsmI effect that we found in COPD patients is consistent with the finding in previous studies of greater quadriceps strength in nonobese elderly women with the b allele (20). It is interesting that the authors of that study found a nonsignificant trend in the opposite direction in obese [body mass index (in kg/m²) > 30] subjects. By contrast, in a study of younger women, the b allele was associated with lower weight and FFM and with lower hamstring strength, although there was no difference in quadriceps strength (19). Another study found lower quadriceps peak torque.
in young Chinese women with the \textit{bb} genotype (41). This discrepancy suggests that the VDR polymorphism may exert different influences in different stages of life or, alternatively, that larger studies are required to resolve the issue.

We previously found an association between quadriceps strength and the I/D polymorphism of the \textit{ACE} gene and the +9/−9 polymorphism of \textit{BK,R} in this group of patients (10, 11). In COPD, the \textit{D} allele of the \textit{ACE} gene (associated with greater tissue \textit{ACE}) was associated with preserved quadriceps strength in a linear fashion across genotype, whereas patients homozygous for the +9 allele (associated with reduced expression of \textit{BK,R}) had less FFM. Neither polymorphism influenced strength or FFM in the control group. In the present study, we found that the effect of \textit{BsmI} genotype was lowest in patients who were homozygous for the \textit{I} allele of the \textit{ACE} gene. Both the \textit{ACE} and \textit{BsmI} polymorphisms affected strength in patients with COPD but not in control subjects. The \textit{ACE} polymorphism has known effects on fiber type: the \textit{D} allele favors Type II fast-twitch fibers and a strength phenotype, whereas the \textit{I} allele is associated with a higher proportion of Type I slow-twitch, fatigue-resistant fibers (42) and a greater response to inflammation (43). This association may be relevant because it is implicated in the loss of skeletal muscle strength in COPD patients, and because vitamin D influences inflammatory responses (14). Thus, the variation in strength associated with the \textit{BsmI} variant may be fiber type–specific, or it may be influenced by the presence of a greater systemic or local inflammatory response. A recent study showed a relation between \textit{ACE} gene polymorphism and secondary hyperparathyroidism in patients on hemodialysis; higher parathyroid concentrations and greater cumulative vitamin D requirements were found in patients with the \textit{DD} genotype than in those \textit{II} (44). The VDR may act by influencing the regulation of insulin-like growth factor (IGF-1)–binding protein (45), which is of interest because muscle-specific expression of IGF-1 has been shown to block angiotensin II–induced muscle wasting (46). Vitamin D itself acts as a potent suppressor of the renin-angiotensin system (14). Thus, the variation in \textit{VDR} expression may be relevant because it is implicated in the loss of skeletal muscle strength in COPD patients, and because vitamin D influences inflammatory responses (14). The VDR is widely distributed and has several different effects. An interesting observation is that the VDR is co-activated by peroxisome proliferator–activated receptor (PPAR) \(\gamma\) coactivator-1\(\alpha\) (PGC-1\(\alpha\)), which is expressed in skeletal muscle and which promotes mitochondrial biogenesis (48). PGC-1\(\alpha\) activates various transcription factors including PPAR\(\alpha\), PPAR\(\delta\), and PPAR\(\gamma\). The PPARs mediate lipid and carbohydrate metabolism in skeletal muscle and may determine fiber type (49, 50). PPAR\(\gamma\) is the target of the glitazone drugs recently introduced to treat insulin resistance, and the \textit{b} allele has been shown to be associated with lower fasting glucose concentrations in young men who did not take part in high levels of physical activity (51).

We acknowledge that data from the subjects in the present study were reported previously. Apart from the polymorphisms described here, no other genetic testing has been carried out, and the decision to investigate the VDR polymorphisms in an existing, well-phenotyped cohort was driven by published data and biological plausibility.

In conclusion, we have identified associations between VDR polymorphisms and strength in patients with COPD. This finding suggests that this receptor has a significant influence on one of the important complications of this disease and that it may be a useful future area for research into mechanisms of skeletal muscle impairment in COPD and other diseases.

The authors’ responsibilities were as follows—NSH, HM, MIP, and JM: study conception; NSH: patient studies and collection of specimens for analysis; KWL, AK, and SHE: genotyping of the samples; NSH, SHE, and MR: statistical analysis; NSH: writing of the first draft of the manuscript; and all authors: contributions to revision of the manuscript and approval of the final version. None of the authors had a personal or financial conflict of interest.

REFERENCES


10. Hopkinson NS, Eleftheriou KI, Payne J, et al. +9/+9 Homozygosity of the \textit{BsmI} allele is associated with reduced expression of the \textit{BsmI} allele in patients who were homozygous for the \textit{I} allele of the \textit{ACE} gene. Both the \textit{ACE} and \textit{BsmI} polymorphisms affected strength in patients with COPD but not in control subjects. The \textit{ACE} polymorphism has known effects on fiber type: the \textit{D} allele favors Type II fast-twitch fibers and a strength phenotype, whereas the \textit{I} allele is associated with a higher proportion of Type I slow-twitch, fatigue-resistant fibers (42) and a greater response to inflammation (43). This association may be relevant because it is implicated in the loss of skeletal muscle strength in COPD patients, and because vitamin D influences inflammatory responses (14). Thus, the variation in strength associated with the \textit{BsmI} variant may be fiber type–specific, or it may be influenced by the presence of a greater systemic or local inflammatory response. A recent study showed a relation between \textit{ACE} gene polymorphism and secondary hyperparathyroidism in patients on hemodialysis; higher parathyroid concentrations and greater cumulative vitamin D requirements were found in patients with the \textit{DD} genotype than in those \textit{II} (44). The VDR may act by influencing the regulation of insulin-like growth factor (IGF-1)–binding protein (45), which is of interest because muscle-specific expression of IGF-1 has been shown to block angiotensin II–induced muscle wasting (46). Vitamin D itself acts as a potent suppressor of the renin-angiotensin system (14). Thus, the variation in \textit{VDR} expression may be relevant because it is implicated in the loss of skeletal muscle strength in COPD patients, and because vitamin D influences inflammatory responses (14). The VDR is widely distributed and has several different effects. An interesting observation is that the VDR is co-activated by peroxisome proliferator–activated receptor (PPAR) \(\gamma\) coactivator-1\(\alpha\) (PGC-1\(\alpha\)), which is expressed in skeletal muscle and which promotes mitochondrial biogenesis (48). PGC-1\(\alpha\) activates various transcription factors including PPAR\(\alpha\), PPAR\(\delta\), and PPAR\(\gamma\). The PPARs mediate lipid and carbohydrate metabolism in skeletal muscle and may determine fiber type (49, 50). PPAR\(\gamma\) is the target of the glitazone drugs recently introduced to treat insulin resistance, and the \textit{b} allele has been shown to be associated with lower fasting glucose concentrations in young men who did not take part in high levels of physical activity (51).

We acknowledge that data from the subjects in the present study were reported previously. Apart from the polymorphisms described here, no other genetic testing has been carried out, and the decision to investigate the VDR polymorphisms in an existing, well-phenotyped cohort was driven by published data and biological plausibility.

In conclusion, we have identified associations between VDR polymorphisms and strength in patients with COPD. This finding suggests that this receptor has a significant influence on one of the important complications of this disease and that it may be a useful future area for research into mechanisms of skeletal muscle impairment in COPD and other diseases.

The authors’ responsibilities were as follows—NSH, HM, MIP, and JM: study conception; NSH: patient studies and collection of specimens for analysis; KWL, AK, and SHE: genotyping of the samples; NSH, SHE, and MR: statistical analysis; NSH: writing of the first draft of the manuscript; and all authors: contributions to revision of the manuscript and approval of the final version. None of the authors had a personal or financial conflict of interest.